Laboratory Parameters in Adolescent Patients Aged 12–17 with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52: Results from the Phase 3 ECZTRA 6 Trial. J of Skin [Internet]. 2024 Jan. 16 [cited 2025 Apr. 6];8(1):s323. Available from: https://skin.dermsquared.com/skin/article/view/2407